Oncology
CuraCell Holding AB is engaged in clinical research for advanced solid tumours, with a focus on metastatic prostate cancer and metastatic colorectal cancer in patients with progressive disease.
- Prostate cancer
- Colorectal cancer
- Locally advanced cancer
- Metastatic disease
The sponsor’s research interest centres on therapies for difficult-to-treat cancer populations where disease progression limits standard treatment options.
Immunotherapy
The clinical programme includes interest in autologous tumor-infiltrating lymphocyte-based treatment approaches, reflecting a focus on cell therapy for solid tumour immunology.
- TIL therapy
- Autologous cell-based immunotherapy
- Tumour-infiltrating lymphocytes
- Anti-tumour immune response
Research activity is directed toward immune-mediated treatment strategies for cancers that remain resistant to conventional approaches.
Clinical safety and tolerability
The sponsor is active in evaluating the safety, tolerability, and practical use of repeated administrations of novel cancer immunotherapies in human subjects.
- Treatment safety
- Tolerability assessment
- Feasibility in clinical use
- Repeated administration
This area of interest supports the development of clinically usable therapies for patients with advanced malignancies.
Advanced cancer care
CuraCell Holding AB’s research landscape includes treatment development for patients with progressive cancer and limited remaining options, especially in metastatic solid tumours.
- Progressive disease
- Advanced malignancy
- Solid tumour oncology
- Therapeutic resistance
The sponsor’s activity is concentrated on clinical research that addresses unmet needs in late-stage cancer populations.
